Sutterlüty H - Search Results

1

The major vault protein is responsive to and interferes with interferon-gamma-mediated STAT1 signals.

Steiner E, Holzmann K, Pirker C, Elbling L, Micksche M, Sutterlüty H, Berger W. Steiner E, et al. Among authors: sutterluty h. J Cell Sci. 2006 Feb 1;119(Pt 3):459-69. doi: 10.1242/jcs.02773. Epub 2006 Jan 17. J Cell Sci. 2006. PMID: 16418217

2

Anticancer activity of the lanthanum compound [tris(1,10-phenanthroline)lanthanum(III)]trithiocyanate (KP772; FFC24).

Heffeter P, Jakupec MA, Körner W, Wild S, von Keyserlingk NG, Elbling L, Zorbas H, Korynevska A, Knasmüller S, Sutterlüty H, Micksche M, Keppler BK, Berger W. Heffeter P, et al. Among authors: sutterluty h. Biochem Pharmacol. 2006 Feb 14;71(4):426-40. doi: 10.1016/j.bcp.2005.11.009. Epub 2005 Dec 15. Biochem Pharmacol. 2006. PMID: 16343446

3

Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms.

Sutterlüty H, Mayer CE, Setinek U, Attems J, Ovtcharov S, Mikula M, Mikulits W, Micksche M, Berger W. Sutterlüty H, et al. Mol Cancer Res. 2007 May;5(5):509-20. doi: 10.1158/1541-7786.MCR-06-0273. Mol Cancer Res. 2007. PMID: 17510316 Free article.

4

Bimodal expression of Sprouty2 during the cell cycle is mediated by phase-specific Ras/MAPK and c-Cbl activities.

Mayer CE, Haigl B, Jantscher F, Siegwart G, Grusch M, Berger W, Sutterlüty H. Mayer CE, et al. Among authors: sutterluty h. Cell Mol Life Sci. 2010 Oct;67(19):3299-311. doi: 10.1007/s00018-010-0379-6. Epub 2010 May 12. Cell Mol Life Sci. 2010. PMID: 20461437 Free PMC article.

5

Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy.

Heinzle C, Sutterlüty H, Grusch M, Grasl-Kraupp B, Berger W, Marian B. Heinzle C, et al. Among authors: sutterluty h. Expert Opin Ther Targets. 2011 Jul;15(7):829-46. doi: 10.1517/14728222.2011.566217. Epub 2011 Mar 7. Expert Opin Ther Targets. 2011. PMID: 21375471 Review.

6

Emerging Roles of Exosomes in Cancer for Possible Clinical Use.

Sutterlüty H, Holzmann K. Sutterlüty H, et al. Cancers (Basel). 2022 Sep 22;14(19):4603. doi: 10.3390/cancers14194603. Cancers (Basel). 2022. PMID: 36230526 Free PMC article.

7

Signal Transduction as an Assimilation of Signals with Different Origins and Different Intracellular States.

Holzmann K, Sutterlüty H. Holzmann K, et al. Among authors: sutterluty h. Int J Mol Sci. 2023 Jun 13;24(12):10085. doi: 10.3390/ijms241210085. Int J Mol Sci. 2023. PMID: 37373232 Free PMC article.

8

A Sprouty4 Mutation Identified in Kallmann Syndrome Increases the Inhibitory Potency of the Protein towards FGF and Connected Processes.

Stütz A, Kamptner AZM, Sutterlüty H. Stütz A, et al. Among authors: sutterluty h. Int J Mol Sci. 2021 Feb 21;22(4):2145. doi: 10.3390/ijms22042145. Int J Mol Sci. 2021. PMID: 33670044 Free PMC article.

9

Sprouty3, but Not Sprouty1, Expression Is Beneficial for the Malignant Potential of Osteosarcoma Cells.

Kamptner AZM, Mayer CE, Sutterlüty H. Kamptner AZM, et al. Among authors: sutterluty h. Int J Mol Sci. 2021 Nov 4;22(21):11944. doi: 10.3390/ijms222111944. Int J Mol Sci. 2021. PMID: 34769378 Free PMC article.

10

NORE1B is a putative tumor suppressor in hepatocarcinogenesis and may act via RASSF1A.

Macheiner D, Gauglhofer C, Rodgarkia-Dara C, Grusch M, Brachner A, Bichler C, Kandioler D, Sutterlüty H, Mikulits W, Schulte-Hermann R, Grasl-Kraupp B. Macheiner D, et al. Among authors: sutterluty h. Cancer Res. 2009 Jan 1;69(1):235-42. doi: 10.1158/0008-5472.CAN-08-2144. Cancer Res. 2009. PMID: 19118008

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

22 results

Search Page

Filters